Prevention is better than cure! The early diagnosis of diseases involves the identification of signaling molecules (biomarkers) or their qualitative/quantitative alterations. Lipidomic, metabolomic, and proteomic studies allow the assessment of the presence and severity of a pathology or the response to pharmacological treatment.
Furthermore, mass spectrometry can be effectively employed to characterize drugs or prodrugs, as well as to characterize and quantify compounds that may be potentially beneficial or harmful to the organisms.